RDInvesting Provides Investors with Free In-Depth Equity Reports on ACPW, KING, LIOX and VRX


Follow this company

Companies Mentioned

NASDAQ:ACPW / NYSE:KING / NASDAQ:LIOX / NYSE:VRX
03/28/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Active Power, Inc. (NASDAQ: ACPW) shares gained 6.35 percent to close at $3.35 a share Thursday. The stock traded between $3.24 and $3.47 on volume of 325,782 shares traded. Analysts at Roth Capital have recently initiated coverage on the company with a "buy" rating. Shares of Active Power have fallen approximately 0.60 percent year-to-date.

Find out more about Active Power including full access to the free equity report at:     
www.RDInvesting.com/ACPW

King Digital Entertainment PLC (NYSE: KING) shares declined 2.68 percent to close at $18.49 a share Thursday. The stock traded between $18.25 and $19.50 on volume of 8.38 million shares traded. Analysts at Sterne Agee have recently initiated coverage on the company with a "neutral" rating. The company fell 15.6 percent on its market debut Wednesday.

Find out more about King Digital Entertainment including full access to the free equity report at: www.RDInvesting.com/KING

Lionbridge Technologies, Inc. (NASDAQ: LIOX) shares increased 0.77 percent to close at $6.55 a share Thursday. The stock traded between $6.36 and $6.61 on volume of 307,097 shares traded. Analysts at Feltl have recently initiated coverage on the company with a "buy" rating and a price target of $8.00. Shares of Lionbridge Technologies have gained approximately 10.0 percent year-to-date.

Find out more about Lionbridge Technologies including full access to the free equity report at:       
www.RDInvesting.com/LIOX

Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares declined 1.46 percent to close at $127.19 a share Thursday. The stock traded between $124.67 and $129.06 on volume of 2.64 million shares traded. Analysts at Cantor Fitzgerald have recently initiated coverage on the company with a "buy" rating and a price target of $200.00. Shares of Valeant Pharmaceuticals have gained approximately 8.0 percent year-to-date.

Find out more about Valeant Pharmaceuticals including full access to the free equity report at:       
www.RDInvesting.com/VRX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:           
Research Driven Investing       
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *